SAVARA INC (SVRA)

Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

Savara Announces New Employment Inducement Grant

Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024

Savara Announces Participation in Upcoming Healthcare Conferences

Savara Reports Third Quarter 2024 Financial Results and Provides Business Update

Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference

Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV

Savara Announces New Employment Inducement Grant

Investors Pick Up SVRA Even Cheaper Than Its Secondary Stock Offering

Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting

Savara Announces New Employment Inducement Grant

Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately

Savara to Host Analyst and Investor Webinar on September 30, 2024

Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024

Savara Announces New Employment Inducement Grant

Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Savara Announces New Employment Inducement Grant

Savara Breaks Above 200-Day Moving Average - Bullish for SVRA

Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024

SVRA Stock Earnings: Savara Misses EPS for Q2 2024

SVRA stock results show that Savara missed analyst estimates for earnings per share the second quarter of 2024.

SVRA Stock Earnings: Savara Misses EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Savara (NASDAQ:SVRA) just reported results for the second quarter of 2024.Savar...

Savara Reports Second Quarter 2024 Financial Results and Provides Business Update

Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock

Notable Wednesday Option Activity: STAA, SVRA, B

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

It's time to dive into the biggest pre-market stock movers as we check out all of the latest news happening on Wednesday morning!

Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

3 Penny Stocks Poised for Major Upside Over the Next 5 Years

These three penny stocks to buy are poised for major upside over the medium-term, for various reasons worth exploring.

3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition

Don’t miss out on these three penny stocks, which have amazing potential to take off following upcoming business developments this year.

Commit To Buy Savara At $4, Earn 51.6% Annualized Using Options

Savara to Present at the Jefferies Global Healthcare Conference

SVRA Crosses Below Key Moving Average Level

Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024

Savara Announces New Employment Inducement Grant

SVRA Stock Earnings: Savara Misses EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Savara (NASDAQ:SVRA) just reported results for the first quarter of 2024.Savara...

SVRA Stock Earnings: Savara Misses EPS for Q1 2024

SVRA stock results show that Savara missed analyst estimates for earnings per share the first quarter of 2024.